Introduction {#H1-1-ZLD200058}
============

Thirty days after a novel therapeutic agent, a new molecular entity, or original biologic is approved, the US Food and Drug Administration (FDA) must publicly disclose its approval package, including scientific reviews completed by FDA disciplines (eg, pharmacology, statistical, and medical reviewers) and any available assessments by agency leadership.^[@zld200058r1]^ Although reports of internal disagreement have surfaced,^[@zld200058r2]^ it is unclear how often such disagreements occur. Disagreements document differing points of view or engaged discussion and may, thus, capture important scientific debates or signal challenging decisions within the agency. We sought to determine the frequency of disagreements within the FDA regarding approval of novel therapeutic agents.

Methods {#H1-2-ZLD200058}
=======

This cross-sectional study did not require institutional review board approval or patient informed consent because it was based on publicly available information and involved no patient records, in accordance with 45 CFR §46. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline for cross-sectional studies.

Between May and September 2019, we identified all approval packages for novel therapeutic agents approved by the FDA from January 2011 to December 2015 using the Drugs\@FDA database. Disagreements were defined as instances where multiple reviewers and/or leadership (whether part of the same discipline or not) disagreed about approving a drug, the indicated patient population (eg, patient age), and/or the parameters of the drug's approval (eg, postmarketing requirements). We searched for disagreements in 2 ways. First, we reviewed the Summary Review, the Office Director Memo, the Cross-Disciplinary Review, and the Medical Review, which tend to describe the recommendations and disagreements. Second, we used key word searches to identify disagreements located elsewhere in the package. The data were extracted by 1 author (A.M.); uncertain cases were resolved through discussion with 2 or 3 other authors (M.H., J.D.W., and A.D.Z.). The frequency of disagreements within and between different disciplines and/or FDA leadership (eg, Division Director) was recorded and tabulated using Excel software version 16.31 (Microsoft Corp). Data analysis was performed from June to November 2019.

Results {#H1-3-ZLD200058}
=======

From 2011 through 2015, the FDA published 174 approval packages for novel therapeutic agents ([Table 1](#zld200058t1){ref-type="table"}). The most common therapeutic areas were cancer (46 agents \[26.4%\]) and infectious diseases (27 agents \[15.5%\]); 72 agents (41.4%) were first in class, and the FDA was the first major regulatory agency to approve the drug for 118 agents (67.8%).

###### Novel Therapeutic Agents Approved 2011-2015

  Year, agent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  2011 (n = 29)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Aflibercept[^a^](#zld200058t1n1){ref-type="table-fn"}Asparaginase erwinia chrysanthemiRuxolitinib phosphateClobazamDeferiproneCrizotinibIcatibant acetate[^b^](#zld200058t1n2){ref-type="table-fn"}^,^[^c^](#zld200058t1n3){ref-type="table-fn"}Brentuximab vedotinVemurafenib                                                                                                                                                                                                                                                  Ticagrelor[^b^](#zld200058t1n2){ref-type="table-fn"}Indacaterol maleateRivaroxabanBelataceptEzogabineFidaxomicinTelaprevirRilpivirine hydrochlorideBoceprevirLinagliptin                                                                                                                                                                                                                                                                                                                                                                                                         Abiraterone acetateGabapentin enacarbilVandetanibIpilimumabBelimumabRoflumilastAzilsartan kamedoxomil[^a^](#zld200058t1n1){ref-type="table-fn"}Vilazodone hydrochloride[^c^](#zld200058t1n3){ref-type="table-fn"}Spinosad
  2012 (n = 36)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Crofelemerb[^b^](#zld200058t1n2){ref-type="table-fn"}Apixaban[^c^](#zld200058t1n3){ref-type="table-fn"}Bedaquiline fumarateLomitapide mesylateTeduglutide recombinantPasireotide diaspartate[^a^](#zld200058t1n1){ref-type="table-fn"}Ponatinib hydrochlorideRaxibacumabCabozantinib s-malateTofacitinib citrateOmacetaxine mepesuccinate[^c^](#zld200058t1n3){ref-type="table-fn"}Perampanel[^c^](#zld200058t1n3){ref-type="table-fn"}^,^[^d^](#zld200058t1n4){ref-type="table-fn"}                                            OcriplasminRegorafenibTeriflunomide[^a^](#zld200058t1n1){ref-type="table-fn"}^,^[^c^](#zld200058t1n3){ref-type="table-fn"}Bosutinib monohydrate[^a^](#zld200058t1n1){ref-type="table-fn"}^,^[^c^](#zld200058t1n3){ref-type="table-fn"}^,^[^d^](#zld200058t1n4){ref-type="table-fn"}EnzalutamideLinaclotide[^a^](#zld200058t1n1){ref-type="table-fn"}^,^[^c^](#zld200058t1n3){ref-type="table-fn"}^,^[^d^](#zld200058t1n4){ref-type="table-fn"}Tbo-filgrastimCobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarateZiv-afliberceptAclidinium bromideCarfilzomib   MirabegronLorcaserin hydrochloridePertuzumab[^b^](#zld200058t1n2){ref-type="table-fn"}Taliglucerase alfaAvanafilPeginesatide acetateLucinactantTafluprostIvacaftorVismodegib[^c^](#zld200058t1n3){ref-type="table-fn"}AxitinibIngenol mebutateGlucarpidase
  2013 (n = 24)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Umeclidinium bromide; vilanterol trifenatateSofosbuvirSimeprevir sodiumLuliconazoleIbrutinibEslicarbazepine acetate[^b^](#zld200058t1n2){ref-type="table-fn"}ObinutuzumabMacitentanRiociguat[^a^](#zld200058t1n1){ref-type="table-fn"}                                                                                                                                                                                                                                                                                          Bazedoxifene acetate; estrogens, conjugatedVortioxetine hydrobromideDolutegravir sodiumAfatinib dimaleateDabrafenib mesylateTrametinib dimethyl sulfoxideRadium Ra-223 dichloride                                                                                                                                                                                                                                                                                                                                                                                                Fluticasone furoate; vilanterol trifenatateCanagliflozin[^a^](#zld200058t1n1){ref-type="table-fn"}^,^[^d^](#zld200058t1n4){ref-type="table-fn"}Dimethyl fumarate[^b^](#zld200058t1n2){ref-type="table-fn"}OspemifeneAdo-trastuzumab emtansinePomalidomideMipomersen sodiumAlogliptin benzoate[^c^](#zld200058t1n3){ref-type="table-fn"}
  2014 (n = 38)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  NivolumabCeftolozane sulfate; tazobactam sodiumDasabuvir sodium; ombitasvir; paritaprevir; ritonavirOlaparib[^a^](#zld200058t1n1){ref-type="table-fn"}PeramivirFinafloxacinBlinatumomabNintedanib esylatePirfenidoneLedipasvir; sofosbuvirNetupitant; palonosetron hydrochloride                                                                                                                                                                                                                                                Dulaglutide[^a^](#zld200058t1n1){ref-type="table-fn"}Naloxegol oxalatePembrolizumabEliglustat tartratePeginterferon beta-1aSuvorexantOritavancin diphosphateEmpagliflozinOlodaterol hydrochlorideIdelalisibTavaboroleBelinostatTedizolid phosphateDalbavancin hydrochloride[^a^](#zld200058t1n1){ref-type="table-fn"}^,^[^b^](#zld200058t1n2){ref-type="table-fn"}                                                                                                                                                                                                               Vedolizumab[^d^](#zld200058t1n4){ref-type="table-fn"}Vorapaxar sulfate[^c^](#zld200058t1n3){ref-type="table-fn"}CeritinibSiltuximabRamucirumab[^c^](#zld200058t1n3){ref-type="table-fn"}AlbiglutideApremilast[^c^](#zld200058t1n3){ref-type="table-fn"}Miltefosine[^c^](#zld200058t1n3){ref-type="table-fn"}MetreleptinDroxidopa[^a^](#zld200058t1n1){ref-type="table-fn"}^,^[^b^](#zld200058t1n2){ref-type="table-fn"}Elosulfase alfaTasimelteonDapagliflozin
  2015 (n = 48)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Lesinurad[^b^](#zld200058t1n2){ref-type="table-fn"}^,^[^c^](#zld200058t1n3){ref-type="table-fn"}Selexipag[^c^](#zld200058t1n3){ref-type="table-fn"}Sugammadex sodiumAlectinib hydrochlorideSebelipase alfaElotuzumabNecitumumabIxazomib citrateDaratumumabOsimertinib mesylateCobimetinib fumarateCobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarateMepolizumab[^c^](#zld200058t1n3){ref-type="table-fn"}^,^[^d^](#zld200058t1n4){ref-type="table-fn"}Asfotase alfaTrabectedinPatiromer sorbitex calcium   Idarucizumab[^c^](#zld200058t1n3){ref-type="table-fn"}Aripiprazole lauroxilInsulin aspart; insulin degludecInsulin degludecTipiracil hydrochloride; trifluridineCariprazine hydrochlorideUridine triacetateRolapitant hydrochlorideEvolocumabFlibanserin[^b^](#zld200058t1n2){ref-type="table-fn"}Alirocumab[^c^](#zld200058t1n3){ref-type="table-fn"}^,^[^d^](#zld200058t1n4){ref-type="table-fn"}Daclatasvir dihydrochlorideSonidegib phosphateBrexpiprazoleSacubitril; valsartan[^a^](#zld200058t1n1){ref-type="table-fn"}Ivacaftor; lumacaftor                               Cangrelor[^a^](#zld200058t1n1){ref-type="table-fn"}^,^[^b^](#zld200058t1n2){ref-type="table-fn"}EluxadolineOlodaterol hydrochloride; tiotropium bromideDeoxycholic acidIvabradine hydrochloride[^a^](#zld200058t1n1){ref-type="table-fn"}^,^[^d^](#zld200058t1n4){ref-type="table-fn"}Cholic acid[^d^](#zld200058t1n4){ref-type="table-fn"}DinutuximabFilgrastim-sndzIsavuconazonium sulfateAvibactam sodium; ceftazidimePanobinostat lactate[^b^](#zld200058t1n2){ref-type="table-fn"}Lenvatinib mesylatePalbociclibParathyroid hormoneSecukinumab[^a^](#zld200058t1n1){ref-type="table-fn"}^,^[^c^](#zld200058t1n3){ref-type="table-fn"}Edoxaban tosylate[^d^](#zld200058t1n4){ref-type="table-fn"}

Denotes approval packages containing 1 or more disagreements pertaining to some other form of disagreement not mentioned in the subsequent footnotes.

Denotes approval packages containing 1 or more disagreements regarding approval.

Denotes approval packages containing 1 or more disagreements pertaining to parameters of approval.

Denotes approval packages containing 1 or more disagreements pertaining to population or indication.

Forty-two (24.1%) approval packages contained at least 1 disagreement: 12 (6.9%) included a disagreement about whether to approve a drug, 10 (5.7%) disagreed over the patient population for which the drug was indicated, and 35 (20.1%) disagreed regarding the parameters of approval, including 20 about postmarketing requirements, safety warnings, or risk evaluation and management strategies, and 15 about other issues, such as drug label phrasing.

Of 155 instances of disagreement, 18 (11.6%) were among reviewers within the same discipline, whereas 137 (88.4%) occurred between different disciplines and/or leadership. The most frequently involved parties were medical reviewers (27 cases \[17.4%\]), members of agency leadership (eg, the Division Director; 33 cases \[21.3%\]), the Cross-Discipline Team Lead (23 cases \[14.8%), and the Office Director (19 cases \[12.3%\]) ([Table 2](#zld200058t2){ref-type="table"}). Among the 12 disagreements regarding approval, 11 were approved with a postmarketing requirement or risk evaluation and management strategy.

###### US Food and Drug Administration Disagreements Over New Drug Approvals, Populations Indicated, and the Parameters of Approval by Subject, Leadership, and Discipline (Total Instances)[^**a**^](#zld200058t2n1){ref-type="table-fn"}

  Variable                                                                                         Approvals (dissents), No.[^b^](#zld200058t2n2){ref-type="table-fn"}   Population or indication, No.   Approval parameters, No.   Other, No.   Total by discipline, No. (%) (n = 155)
  ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------- ------------------------------- -------------------------- ------------ ----------------------------------------
  Agency leadership                                                                                                                                                                                                                              
  Division director                                                                                9 (1)                                                                 8                               10                         6            33 (21.3)
  Office director                                                                                  5 (0)                                                                 2                               8                          4            19 (12.3)
  Cross-disciplinary team leader                                                                   8 (4)                                                                 5                               6                          4            23 (14.8)
  Agency disciplines                                                                                                                                                                                                                             
  Medical                                                                                          6 (5)                                                                 6                               8                          7            27 (17.4)
  Clinical pharmacology                                                                            2 (1)                                                                 2                               3                          5            12 (7.7)
  Statistics                                                                                       4 (3)                                                                 4                               1                          3            12 (7.7)
  Safety                                                                                           1 (1)                                                                 5                               5                          1            12 (7.7)
  Pediatric                                                                                        0 (0)                                                                 1                               3                          1            5 (3.2)
  Chemistry                                                                                        4 (1)                                                                 0                               0                          0            4 (2.6)
  Nonclinical pharmacology                                                                         1 (0)                                                                 0                               2                          1            4 (2.6)
  Office of Scientific Investigations and other reviewers of regulatory issues                     1 (0)                                                                 0                               1                          0            2 (1.3)
  Division of Risk Management and other reviewers of the Risk Evaluation and Mitigation Strategy   0 (0)                                                                 0                               2                          0            2 (1.3)
  Microbiology                                                                                     0 (0)                                                                 0                               0                          0            0 (0.0)
  Total by subject (n = 155)                                                                       41                                                                    33                              49                         32           

In 8 cases, the other party disagreeing with the disciplines listed here was not a member of 1 of the standard disciplines or leadership that are listed here. For example, in the case of the novel therapeutic agent sacubitril-valsartan (Entresto), a reviewer filed a nonstandard unsolicited review containing conclusions with which members of the standard disciplines disagreed.

The number in parentheses reflects the number of disagreements in which the discipline (or leadership) was the party recommending against approval. These numbers do not include within-discipline dissents, in which 1 reviewer recommended against approval but the discipline as a whole ultimately supported approval.

Discussion {#H1-4-ZLD200058}
==========

Among all approval packages for novel therapeutics approved by the FDA from 2011 to 2015, disagreements were common over new drug approvals, populations indicated, and the specific parameters of the approval. Given the complexity of determining drug safety and efficacy and the challenge of extrapolating to broad populations from a limited number of small, narrowly defined clinical trials,^[@zld200058r3]^ disagreements within the FDA are not surprising and likely represent differing points of view that may inform pharmacovigilance efforts, as well as public discourse.^[@zld200058r4]^

Our study was limited to disagreements recorded within approval packages. Where disagreements may be unrecorded, our analysis may underestimate their prevalence. We also did not assess whether disagreements were discussed by advisory committees or associated with particular outcomes (eg, safety warnings discovered after approval).

Nevertheless, our findings have important implications for the FDA's recent move to publish only integrated reviews in lieu of reviews by each discipline and agency leadership.^[@zld200058r5]^ It raises questions about whether disagreements within the agency will continue to be published in compliance with the law.^[@zld200058r1],[@zld200058r6]^
